

Ad hoc announcement pursuant to Art. 53 LR

Basel, 22 October 2026

Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026

- **Group sales** were +6% at constant exchange rates (CER)¹, +1% when reported in CHF and +7% in USD², in the first nine months of 2026, driven by high demand for our innovative medicines and diagnostics. In the third quarter, sales grew +7% (CER) and +8% in CHF (+7% in USD), as exchange rates stabilised.
- **Pharmaceuticals Division sales** were +7% at CER, +2% when reported in CHF and +8% in USD, in the first nine months, due to continued high demand for medicines to treat severe diseases; Xolair (chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.
- **Diagnostics Division sales** were +4% at CER, stable when reported in CHF and +6% in USD, in the first nine months, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.
- **Highlights:**
 - US approval for **Tecentriq** for the adjuvant treatment of stage-III DNA mismatch repair colon cancer, **Gazyva/Gazyvaro** for reducing the risk of relapse in patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome and **Enspryng** in thyroid eye disease
 - US Priority Reviews for **fenebrutinib** in both relapsing and primary progressive multiple sclerosis and **Enspryng** in MOGAD, an autoimmune disease; **vamikibart** filing acceptance in uveitic macular edema, a leading cause of vision loss
 - EU approval for **Susvimo** in neovascular age-related macular degeneration (nAMD), a severe eye disease, and **Ocrevus** in paediatric relapsing multiple sclerosis; EMA validation of application for **Enspryng** in MOGAD in Europe

- Positive data for: **sefaxersen** in an autoimmune condition affecting kidney function (phase III), **Lunsumio** in blood cancer (phase III), **Tam-Peli** in relapsed small-cell lung cancer (phase III) as well as **enicepatide** and **petrelintide** in overweight or obesity and type 2 diabetes (both phase II)
 - US clearance for **Elecsys pTau217 test**, providing clinicians across primary and specialty care with a single-biomarker blood test to aid in identifying amyloid pathology associated with Alzheimer's disease
 - Launch of two new, real-time **PCR tests** to support public health epidemic response to the US outbreak of the *Cyclospora cayetanensis* parasite
 - Delivery of **molecular tests** to support the Democratic Republic of the Congo health ministry-led response to the Ebola outbreak
 - Manufacturing and R&D capacity expansion: **Hillsboro** injectable medicines facility and **Innovation Center Boston for cardiovascular, renal and metabolic diseases** in the US and **small molecules facility** in Basel, Switzerland
- **Outlook for 2026 confirmed**

Roche CEO Thomas Schinecker: “In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs.

Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030.

The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval.

In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer's disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.

We confirm our full-year outlook.”

Outlook for 2026

Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs.

Sales January–September	CHF millions		As % of sales		% change		
	2026	2025	2026	2025	At CER	In CHF	In USD
Group	46,493	45,862	100.0	100.0	+6	+1	+7
Pharmaceuticals Division	36,212	35,555	77.9	77.5	+7	+2	+8
United States	18,712	18,798	40.2	41.0	+5	0	
Europe	6,819	6,818	14.7	14.9	+2	0	
Japan	2,352	2,139	5.1	4.7	+25	+10	
International	8,329	7,800	17.9	16.9	+10	+7	
Diagnostics Division	10,281	10,307	22.1	22.5	+4	0	+6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Group sales

In the first nine months of 2026, Roche **sales** were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. This currency impact reversed in the third quarter.

Sales growth in the **Pharmaceuticals Division** was +7% at CER, +2% when reported in CHF, to CHF 36.2 billion, with medicines for severe diseases continuing their strong growth.

The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 16.8 billion, an increase of +12% at CER, or +6% in CHF, compared to the first nine months of 2025.

Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.4 billion at CER, or CHF 0.6 billion in CHF.

In the **United States**, sales were +5% at CER, stable when reported in CHF, due to continued growth of Xolair, Hemlibra, Ocrevus, Polivy (blood cancer) and Tecentriq (cancer immunotherapy). This growth more than compensated for the lower sales of Kadcyla (breast cancer) and Perjeta (breast cancer).

Sales in **Europe** were +2% at CER, stable when reported in CHF, as the growing demand for Ocrevus, Phesgo and Evrysdi (spinal muscular atrophy) more than offset the impact of biosimilar competition on Actemra/RoActemra and the conversion to Phesgo on Perjeta.

In **Japan**, sales were +25% at CER, +10% when reported in CHF, mainly due to product supply to third parties and continued growth of Lunsumio (blood cancer), Hemlibra, Polivy, Elevidys (Duchenne muscular dystrophy) and Vabysmo. There was also a positive impact of timing effects related to the implementation of a new enterprise resource planning (ERP) system.

Sales in the **International** region were +10% at CER, +7% when reported in CHF, led by higher sales of Phesgo, Vabysmo, Hemlibra, Ocrevus and Evrysdi. In China, sales were stable at CER and when reported in CHF, driven by continued growth of Phesgo, Vabysmo, Alecensa and Polivy. The increase was partially offset by lower sales of Perjeta due to the conversion to Phesgo and Xofluza due to a milder flu season in 2025.

The **Diagnostics Division's** sales were +4% at CER, stable when reported in CHF, to CHF 10.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.

Sales in the **Europe, Middle East and Africa (EMEA)** region were +3% at CER, unchanged when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In **North America**, sales were +9% at CER, +3% when reported in CHF, with growth across the Core Lab, Pathology Lab and Molecular Lab customer areas. Sales in **Asia-Pacific** were -4% at CER, or -8% when reported in CHF, due to the healthcare pricing reforms in China. In **Latin America**, sales growth was +12% at CER, or +11% when reported in CHF.

Pharmaceuticals: key developments

Compound	Milestone
Regulatory	
Enspryng Thyroid eye disease	FDA approves Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) ● FDA approval based on phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration. ● Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home subcutaneous treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered. ● Enspryng is an anti-IL-6R monoclonal antibody using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology. ● TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated.
Tecentriq Different types of cancer	FDA approves Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer ● The approval is based on results from the landmark phase III ATOMIC study, published in <i>The New England Journal of Medicine</i>, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. ● It is the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care. ● Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years. ● Approval marks the twelfth indication for Tecentriq in the US.
Fenebrutinib Multiple sclerosis	Fenebrutinib is the first BTK inhibitor to receive US FDA filing acceptance in both relapsing and primary progressive multiple sclerosis ● Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in phase III RMS trials (FENhance 1 and 2) while showing a consistent, positive trend in delaying disability. ● Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a phase III PPMS trial (FENTrepid), with numerical benefit vs Ocrevus. ● Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression.

	● If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million people living with MS in the US.
Susvimo Severe eye diseases	European Commission approves Susvimo for the treatment of neovascular age-related macular degeneration ● By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD. ● Susvimo helps people with nAMD maintain their vision with as few as two treatments per year. ● Data from the phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections. ● nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European Union.
Enspryng MOGAD	FDA grants Priority Review for Enspryng for MOGAD, an autoimmune disease with no approved treatments ● If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease). ● The filing acceptance is based on the phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%. ● The European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe, with a decision expected in Q3 2027.
Phase III, pivotal and other key read-outs	
Sefaxersen IgA nephropathy	Positive interim data shows sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) ● In the phase III IMaGINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential. ● Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage. ● Interim data will be presented at an upcoming medical meeting and shared with health authorities.
Enicepatide Obesity	Roche announces positive phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity ● At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycaemic control. ● By week 48, 90% of patients in the 24 mg enicepatide arm met the type-2 diabetes glycaemic target of $\leq 6.5\%$ HbA1c, while 62% achieved normoglycaemia (HbA1c $< 5.7\%$). ● At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau.

Lunsumio Blood cancer	Regimen based on Lunsumio significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study ● Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment. ● Data reinforce the potential of this regimen based on Lunsumio to improve clinical outcomes, while offering a tolerable safety profile, a simple dosing schedule and outpatient administration. ● CELESTIMO is the confirmatory study required to convert the accelerated approval / conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) follicular lymphoma to full approval, as well as to secure an indication in second-line or later (2L+) follicular lymphoma. ● Data will be submitted to health authorities and presented at an upcoming medical meeting.
Tam-Peli Lung cancer	Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer ● Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%. ● The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink's proprietary TMALIN platform, designed to maximise antitumour activity while minimising off-target toxicity. ● Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau across multiple tumour types, with plans to rapidly initiate global trials. Tam-Peli has received US FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer.
Vabysmo Severe eye diseases	Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of nAMD ● The SALWEEN study showed significant improvements in vision and retinal health. ● More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions. ● By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden.
Other	
ESMO presentation Lung and breast cancer portfolio	Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio ● Phase III Krascendo 1 results demonstrated divarasib's superiority over current standard-of-care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer. ● Patient-reported outcomes from phase III lidERA study showed that improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer.

	Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours.
Vamikibart Uveitic macular edema	Roche presents new phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss - In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks. - UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated. - The FDA has accepted Roche's Biologics License Application (BLA), with an approval decision expected by July 2027.
Vabysmo Severe eye diseases	Roche presents new data at EURETINA, highlighting the real-world effectiveness and safety of Vabysmo across major retinal conditions - New real-world results for Vabysmo in nAMD, diabetic macular edema and retinal vein occlusion reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals. - Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care. - With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide.
Giredestrant Breast cancer	Giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in <i>The New England Journal of Medicine</i> - Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus. - By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes. - The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026.
Board of Directors nomination	Roche proposes Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board of Directors at the 2027 Annual General Meeting - Roche's Board of Directors has approved to propose Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board at the Annual General Meeting on 9 March 2027. - Roche Chairman Severin Schwan highlighted Dr Weber's extensive healthcare industry knowledge and leadership experience as valuable assets for the Board. - Roche continues its commitment to transformative medicines and diagnostics, focusing on major disease areas and global healthcare challenges.

Innovation Center Boston	Roche announces grand opening of its Innovation Center Boston to drive advancements in cardiovascular, renal and metabolic diseases ● The centre will be a hub for Roche and Genentech, bringing together expertise in cardiovascular, renal and metabolic diseases, as well as for data science and AI specialists to drive innovation in drug discovery and development. ● It will expand Roche's and Genentech's presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs. ● This is part of Roche and Genentech's USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon.
Hillsboro facility	Genentech, Roche's US subsidiary, announces a USD 750 million manufacturing expansion in Hillsboro, Oregon ● The new facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end US drug manufacturing capabilities. ● Approximately USD 750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs. ● Flexible manufacturing capacity will support advanced drug delivery devices that can provide patients with more convenient ways to receive treatment.

Pharmaceuticals sales

Sales	CHF millions		As % of sales		% change	
January–September	2026	2025	2026	2025	At CER	In CHF
Pharmaceuticals Division	36,212	35,555	100.0	100.0	+7	+2
United States	18,712	18,798	51.7	52.9	+5	0
Europe	6,819	6,818	18.8	19.2	+2	0
Japan	2,352	2,139	6.5	6.0	+25	+10
International	8,329	7,800	23.0	21.9	+10	+7

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Top 20 best-selling pharmaceuticals (% change at CER ¹)	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus Multiple sclerosis	5,317	+7	3,581	+5	1,136	+9	-	-	600	+21
Hemlibra Haemophilia A	3,750	+12	2,006	+9	769	+5	291	+20	684	+23
Vabysmo Eye diseases (nAMD, DME, RVO)	3,196	+10	2,060	+2	585	+7	131	+41	420	+65
Tecentriq Cancer immunotherapy	2,615	+5	1,243	+8	626	-2	245	+6	501	+9
Xolair ³ Chronic hives, food allergies	2,521	+20	2,521	+20	-	-	-	-	-	-
Phesgo Breast cancer	2,064	+18	486	-1	657	+11	152	+24	769	+43
Perjeta ³ Breast cancer	2,040	-8	824	-10	361	-13	38	-20	817	-3
Actemra/RoActemra ³ RA, COVID-19	1,621	-10	795	-9	328	-26	232	+14	266	-4
Evrysdi Spinal muscular atrophy	1,470	+18	497	+12	504	+14	65	+7	404	+33
Kadcyla ³ Breast cancer	1,339	-9	442	-19	370	-5	65	+9	462	-2
Polivy Blood cancer	1,302	+24	606	+29	204	-9	176	+30	316	+44
Alecensa Lung cancer	1,213	+6	391	-1	189	-3	154	+15	479	+15
MabThera/Rituxan ³ Blood cancer, RA	919	+3	605	+12	94	-8	8	-16	212	-10
Activase/TNKase ³ Cardiac diseases	830	+6	792	+5	-	-	-	-	38	+12
Gazyva/Gazyvaro ³ Blood cancer, lupus nephritis	751	+7	369	+4	176	-2	28	+28	178	+25
Herceptin ³ Breast and gastric cancer	695	-12	140	-15	205	-6	3	-35	347	-13
Avastin ³ Various cancer types	639	-12	195	-8	56	+5	56	-43	332	-9
Columvi Blood cancer	327	+67	146	+24	92	+113	-	-	89	+167

Enspryng Acute inflammation of brain, spinal cord and optic nerves	319	+28	79	+18	34	+18	138	+30	68	+42
Pulmozyme³ Cystic fibrosis	303	-12	214	-11	43	-11	1	+38	45	-18

DME: diabetic macular edema / nAMD: neovascular or 'wet' age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis

Diagnostics: key developments

Product	Milestone
Elecsys pTau217 Alzheimer's disease	Roche receives FDA clearance for Elecsys pTau217, advancing Alzheimer's disease assessment across primary and specialty care - It is the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. - The test delivers consistency across clinical settings by using the same validated cut-offs in primary and specialty care. - It is designed for broad implementation across Roche's installed base of more than 4,500 cobas laboratory instruments in the US supporting access through existing laboratory infrastructure.

Diagnostics sales

Sales	CHF millions		As % of sales		% change	
January–September	2026	2025	2026	2025	At CER	In CHF
Diagnostics Division	10,281	10,307	100.0	100.0	+4	0
Customer areas						
Core Lab	5,755	5,688	56.0	55.2	+5	+1
Molecular Lab	1,836	1,861	17.9	18.1	+3	-1
Near Patient Care	1,348	1,477	13.1	14.3	-5	-9
Pathology Lab	1,342	1,281	13.0	12.4	+10	+5

Regions						
Europe, Middle East, Africa	3,698	3,686	36.0	35.8	+3	0
North America	3,389	3,305	32.9	32.1	+9	+3
Asia-Pacific	2,343	2,547	22.8	24.7	-4	-8
Latin America	851	769	8.3	7.4	+12	+11

Third Quarter Sales 2026 Webinar

There will be a live webinar for investors and analysts today, Thursday, 22 October at 2:00 pm CEST. To access the webinar, please click [here](#).

Additional information

Third Quarter Sales 2026 Presentation: <http://www.roche.com/irp261022-a.pdf>

Third Quarter Sales 2026 Presentation with appendix: <http://www.roche.com/irp261022.pdf>

Pharmaceuticals: key product launches in 2026: www.roche.com/pharmaq326.pdf

Diagnostics: key product launches in 2026: www.roche.com/diaq326.pdf

About Roche

Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

- [1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025.
- [2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies.
- [3] Products launched before 2015.

Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Roche Global Media Relations

Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz

Phone: +41 79 529 70 35

Lorena Corfas

Phone: +41 79 568 24 95

Simon Goldsborough

Phone: +44 797 32 72 915

Karsten Kleine

Phone: +41 79 461 86 83

Kirti Pandey

Phone: +41 79 398 38 53

Yvette Petillon

Phone: +41 79 961 92 50

Irène Stephan

Phone: +41 79 377 83 75

Albert Thottiyil

Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli

Phone: +41 61 687 5 284

e-mail: bruno.eschli@roche.com

Dr Sabine Borngräber

Phone: +41 61 688 80 27

e-mail: sabine.borngraeber@roche.com

Dr Birgit Masjost

Phone: +41 61 688 48 14

e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com

Appendix: Tables

1.	Sales January to September 2026 and 2025	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2026 vs. YTD September 2025	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to September 2026 and 2025

CHF millions	Nine months ended 30 September		% change	
	2026	2025	At CER	In CHF
Pharmaceuticals Division	36,212	35,555	7	2
United States	18,712	18,798	5	0
Europe	6,819	6,818	2	0
Japan	2,352	2,139	25	10
International	8,329	7,800	10	7
Diagnostics Division	10,281	10,307	4	0
Roche Group	46,493	45,862	6	1

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Pharmaceuticals Division	11,570	7	12,114	9	11,469	7	12,160	6	12,583	8
United States	6,128	5	6,557	9	5,693	5	6,536	7	6,483	5
Europe	2,252	5	2,346	7	2,234	-1	2,286	3	2,299	2
Japan	714	6	743	4	649	14	711	9	992	49
International	2,476	11	2,468	16	2,893	16	2,627	4	2,809	11
Diagnostics Division	3,348	2	3,540	6	3,253	3	3,482	4	3,546	5
Roche Group	14,918	6	15,654	8	14,722	6	15,642	5	16,129	7

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2026 vs. YTD September 2025

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,317	7	3,581	5	1,136	9	-	-	600	21
Hemlibra	3,750	12	2,006	9	769	5	291	20	684	23
Vabysmo	3,196	10	2,060	2	585	7	131	41	420	65
Tecentriq	2,615	5	1,243	8	626	-2	245	6	501	9
Xolair	2,521	20	2,521	20	-	-	-	-	-	-
Phesgo	2,064	18	486	-1	657	11	152	24	769	43
Perjeta	2,040	-8	824	-10	361	-13	38	-20	817	-3
Actemra/RoActemra	1,621	-10	795	-9	328	-26	232	14	266	-4
Evrysdi	1,470	18	497	12	504	14	65	7	404	33
Kadcyla	1,339	-9	442	-19	370	-5	65	9	462	-2
Polivy	1,302	24	606	29	204	-9	176	30	316	44
Alecensa	1,213	6	391	-1	189	-3	154	15	479	15
MabThera/Rituxan	919	3	605	12	94	-8	8	-16	212	-10
Activase/TNKase	830	6	792	5	-	-	-	-	38	12
Gazyva	751	7	369	4	176	-2	28	28	178	25
Herceptin	695	-12	140	-15	205	-6	3	-35	347	-13
Avastin	639	-12	195	-8	56	5	56	-43	332	-9
Columvi	327	67	146	24	92	113	-	-	89	167
Enspryng	319	28	79	18	34	18	138	30	68	42
Pulmozyme	303	-12	214	-11	43	-11	1	38	45	-18
Elevidys	291	37	-	-	2	-	40	-	249	16
Lunsumio	206	187	108	155	14	-15	78	*	6	79
Xofluza	185	-24	37	24	3	46	-	-	145	-32

Itovebi	163	153	129	124	12	*	-	-	22	308
Rozlytrek	102	-8	25	-28	18	8	4	-9	55	1
PiaSky	52	74	1	207	11	138	39	61	1	58
Cotellic	35	5	17	9	7	-5	-	-	11	6
Luxturna	26	-29	26	-29	-	-	-	-	-	-
Susvimo	12	107	12	106	-	-	-	-	-	-
Pharma other	1,909	-1	365	-13	323	-3	408	47	813	-11
Pharma total sales	36,212	7	18,712	5	6,819	2	2,352	25	8,329	10

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	1,684	6	1,820	16	1,692	6	1,778	7	1,847	9
Hemlibra	1,105	4	1,228	8	1,190	13	1,302	9	1,258	13
Vabysmo	996	4	1,039	7	1,024	13	1,035	3	1,137	13
Tecentriq	883	4	950	8	811	4	893	9	911	3
Xolair	781	34	849	26	708	26	965	28	848	8
Phesgo	630	51	614	34	686	27	632	9	746	18
Perjeta	703	-14	652	-13	672	-11	717	-3	651	-9
Actemra/RoActemra	614	-2	577	-10	534	-4	540	-14	547	-11
Evrysdi	424	10	464	26	464	19	504	16	502	18
Kadcyla	494	7	494	6	439	-4	477	-7	423	-15
Polivy	371	30	369	31	407	26	401	14	494	33
Alecensa	388	8	372	1	401	12	394	1	418	6
MabThera/Rituxan	303	3	318	-3	292	10	317	0	310	1
Activase/TNKase	283	1	274	-2	255	-2	300	24	275	-4
Gazyva	238	13	258	15	247	10	242	4	262	9
Herceptin	257	-15	211	-29	234	-12	228	-12	233	-11
Avastin	241	-11	210	-21	224	-9	190	-20	225	-8
Columvi	79	71	86	64	95	77	101	64	131	63
Enspryng	92	25	95	17	96	31	99	15	124	37
Pulmozyme	122	26	118	1	89	-18	115	3	99	-20

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	1,151	1	1,261	17	1,117	3	1,183	2	1,281	10
Hemlibra	617	-1	724	6	613	15	700	4	693	11
Vabysmo	689	-4	718	-1	652	4	681	-2	727	4
Tecentriq	403	2	418	4	378	6	437	12	428	5
Xolair	781	34	849	26	708	26	965	28	848	8
Phesgo	175	29	185	22	159	2	159	-2	168	-5
Perjeta	291	-6	300	4	263	-12	288	-10	273	-8
Actemra/RoActemra	307	-6	280	-19	248	-3	267	-13	280	-10
Evrysdi	159	18	144	0	160	15	163	15	174	8
Kadcyla	181	2	191	10	156	-11	154	-17	132	-28
Polivy	170	18	191	32	171	26	210	29	225	32
Alecensa	144	15	145	4	105	-7	156	13	130	-10
MabThera/Rituxan	188	5	219	5	183	16	219	13	203	7
Activase/TNKase	270	1	259	-2	244	-2	287	24	261	-5
Gazyva	123	14	143	20	115	1	125	8	129	3
Herceptin	54	-6	50	-14	44	-16	50	-13	46	-18
Avastin	69	-16	74	-14	59	-15	66	-8	70	0
Columvi	47	90	53	70	43	35	48	23	55	17
Enspryng	25	9	26	1	22	20	28	20	29	15
Pulmozyme	87	30	89	8	58	-21	87	11	69	-22

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	354	12	391	14	363	9	395	11	378	7
Hemlibra	247	14	262	12	252	5	250	3	267	8
Vabysmo	178	9	185	13	190	0	196	10	199	11
Tecentriq	216	0	228	7	202	-6	208	-1	216	0
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	201	9	210	9	206	7	219	10	232	15
Perjeta	136	-14	134	-7	119	-15	119	-12	123	-10
Actemra/RoActemra	142	-1	138	-7	124	-16	114	-27	90	-36
Evrysdi	158	7	166	21	159	13	176	21	169	8
Kadcyla	130	-5	136	0	123	-6	125	-3	122	-7
Polivy	68	21	62	26	63	-32	65	1	76	12
Alecensa	64	-10	65	-3	63	-5	63	-2	63	-1
MabThera/Rituxan	34	13	36	-13	31	-8	31	-9	32	-7
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	62	1	62	5	57	-2	60	-1	59	-5
Herceptin	73	2	68	-9	69	-7	67	-6	69	-5
Avastin	28	47	16	-22	14	3	21	76	21	-25
Columvi	18	51	19	65	21	84	32	142	39	110
Enspryng	11	37	10	36	11	20	12	21	11	13
Pulmozyme	15	-3	16	-9	15	-14	14	-7	14	-11

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	92	11	102	5	81	18	90	3	120	40
Vabysmo	35	17	41	15	37	39	38	16	56	68
Tecentriq	88	-1	87	-6	69	0	77	-4	99	21
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	49	41	49	11	42	23	46	8	64	39
Perjeta	17	-27	15	-31	12	-19	12	-26	14	-15
Actemra/RoActemra	78	4	80	6	66	9	74	7	92	26
Evrysdi	22	7	22	-9	18	4	21	-5	26	24
Kadcyla	23	-2	23	-7	19	6	20	-1	26	23
Polivy	54	14	54	5	46	24	52	10	78	54
Alecensa	51	13	53	7	43	4	50	12	61	27
MabThera/Rituxan	4	-3	3	-11	3	-6	3	-16	2	-26
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	8	22	10	37	9	28	8	0	11	60
Herceptin	2	-30	1	-33	1	-24	1	-47	1	-33
Avastin	35	-19	34	-21	21	-29	15	-56	20	-41
Columvi	-	-	-	-	-	-	-	-	-	-
Enspryng	42	22	44	20	35	13	44	22	59	52
Pulmozyme	-	13	1	-21	-	43	-	14	1	59

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	179	35	168	11	212	24	200	37	188	6
Hemlibra	149	9	140	18	244	14	262	39	178	18
Vabysmo	94	111	95	118	145	126	120	24	155	64
Tecentriq	176	17	217	25	162	14	171	20	168	-5
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	205	213	170	122	279	78	208	19	282	36
Perjeta	259	-21	203	-30	278	-9	298	10	241	-10
Actemra/RoActemra	87	7	79	6	96	5	85	-10	85	-6
Evrysdi	85	4	132	116	127	40	144	14	133	54
Kadcyla	160	28	144	9	141	5	178	1	143	-11
Polivy	79	105	62	67	127	120	74	-7	115	38
Alecensa	129	8	109	-3	190	39	125	-13	164	21
MabThera/Rituxan	77	-5	60	-22	75	6	64	-24	73	-10
Activase/TNKase	13	18	15	-4	11	-4	13	29	14	13
Gazyva	45	24	43	8	66	45	49	-1	63	32
Herceptin	128	-25	92	-42	120	-14	110	-14	117	-12
Avastin	109	-13	86	-26	130	-1	88	-26	114	1
Columvi	14	48	14	45	31	204	21	135	37	158
Enspryng	14	60	15	32	28	93	15	-11	25	52
Pulmozyme	20	34	12	-19	16	-12	14	-24	15	-17

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others